In April 2025, Isomorphic Labs raised a $600 million in its first-ever external funding round, led by Thrive Capital. Alphabet’s Isomorphic Labs is preparing to launch human trials of AI-designed ...
Isomorphic Labs has raised $600m in its first external funding round as it pushes forward with artificial intelligence (AI)-driven drug discovery. Thrive Capital led the financing round, with ...
Isomorphic Labs will utilise the funding to further power its AI drug design engine through frontier AI research and development and to scale and progress its drug candidate pipeline. Isomorphic Labs ...
On a rare sunny day in London at the Google DeepMind office, Colin Murdoch saw the bank deposit from his employer come through. It wasn't his paycheck. Google was investing in his startup. The ...
Isomorphic Labs, the London-based, drug discovery–focused spinout of Google AI R&D division DeepMind, today announced that it’s entered into strategic partnerships with two pharmaceutical giants, Eli ...
Isomorphic Labs, a London-based spin-out of Alphabet Inc (NASDAQ:GOOG) (NASDAQ:GOOGL) Google's AI R&D division DeepMind, has announced strategic partnerships with Eli Lilly And Co (NYSE:LLY) and ...
Hosted on MSN
Inside Isomorphic Labs, the secretive AI life sciences startup spun off from Google DeepMind
Isomorphic Labs was spun out of Google DeepMind, after the tech giant achieved one of the biggest biological breakthroughs in the last 50 years. Demis Hassabis is at the helm of both Isomorphic and ...
Alphabet’s Isomorphic Labs is preparing to launch human trials of AI-designed drugs, its president, Colin Murdoch, told Fortune. Born from DeepMind’s AlphaFold breakthrough, the company is pairing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback